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Abstract 
Background: The sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been reported to increase both low-den-
sity lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol (C). This study aimed to determine how SGLT-2 
inhibitors affect LDL and HDL-C subspecies.
Methods: This single center, open-label, randomized, prospective study included 80 patients with type 2 diabetes 
taking prescribed oral hypoglycemic agents. Patients were allocated to receive dapagliflozin (n = 40) or sitagliptin 
(n = 40) as add-on treatment. Fasting blood samples were collected before and 12 weeks after this intervention. 
Small dense (sd) LDL-C, large buoyant (lb) LDL-C, HDL2-C, and HDL3-C levels were determined using our established 
homogeneous assays. Statistical comparison of blood parameters before and after treatment was performed using 
the paired t test.
Results: Dapagliflozin and sitagliptin comparably decreased HbA1c (0.75 and 0.63%, respectively). Dapagliflozin sig-
nificantly decreased body weight, systolic blood pressure, plasma triglycerides and liver transaminases, and increased 
adiponectin; sitagliptin did not alter these measurements. LDL-C and apolipoprotein (apo) B were not significantly 
changed by dapagliflozin, whereas HDL-C and apo AI were increased. Dapagliflozin did not alter concentrations 
of LDL-C, but sd LDL-C decreased by 20% and lb LDL-C increased by 18%. Marked elevation in lb LDL-C (53%) was 
observed in individuals (n = 20) whose LDL-C was elevated by dapagliflozin. However, sd LDL-C remained suppressed 
(20%). Dapagliflozin increased HDL2-C by 18% without affecting HDL3-C. Sitagliptin did not alter plasma lipids or 
lipoprotein subspecies.
Conclusions: A SGLT-2 inhibitor, dapagliflozin suppresses potent atherogenic sd LDL-C and increased HDL2-C, a 
favorable cardiometabolic marker. Although LDL-C levels are elevated by treatment with dapagliflozin, this was due to 
increased concentrations of the less atherogenic lb LDL-C. However, these findings were not observed after treatment 
with dipeptidyl peptidase-4 inhibitor, sitagliptin.
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Background
Recently, sodium-glucose co-transporter-2 (SGLT-2) 
inhibitors have been developed as novel therapeutic 
agents for the treatment of type 2 diabetes [1–3]. These 
drugs inhibit the reabsorption of glucose in the proxi-
mal tubules of the kidney, leading to increased urinary 
excretion of glucose and decreased levels of blood glu-
cose in diabetic patients [1–3]. In addition, use of SGLT-2 
inhibitors results in decreased body weight and visceral 
fat mass, and reduced blood pressure. These factors are 
expected to suppress adverse cardiovascular outcomes 
[1–3]. In a secondary prevention study (the EMPA-REG 
OUTCOME® trial), empagliflozin successfully sup-
pressed composite adverse cardiovascular outcomes [4]. 
However, it remains unclear whether SGLT-2 inhibitors 
prevent cardiovascular events in cardiovascular dis-
ease-free diabetic patients. Several clinical studies have 
revealed that SGLT-2 inhibitors decrease plasma triglyc-
eride (TG) levels and increase high-density lipoprotein 
(HDL)-cholesterol (C) (HDL-C) levels, but also increase 
low-density lipoprotein (LDL)-C (LDL-C) levels [5, 6]. 
LDL-C is the most powerful determinant of cardiovascu-
lar events in patients with type 2 diabetes [7, 8], thus, the 
increased levels of LDL-C associated with SGLT-2 inhibi-
tor use might increase cardiovascular risk.
LDL-C can be fractionated into large buoyant (lb) and 
small dense (sd) particles based on size and density. An 
abundance of clinical evidence has shown that sd LDL-C 
particles are more atherogenic than lb LDL-C particles, 
and that the predominance of sd LDL-C confers a three-
fold increased risk for coronary artery disease [9], as sd 
LDL-C forms a good substrate for oxidized LDL-C in 
the arterial wall [10]. LDL size is inversely regulated by 
plasma TG levels [11] and insulin resistance [12]. There 
is a preponderance of sd LDL-C particles in individuals 
with hypertriglyceridemia, metabolic syndrome [13], and 
type 2 diabetes [14].
We established a homogeneous assay for the direct 
measurement of serum sd LDL-C concentrations [15]. 
This assay has been used in well-known, large cohort 
studies which revealed that sd LDL-C concentrations 
more sensitively predicted cardiovascular events than 
did LDL-C or lb LDL-C concentrations [16–18]. We 
hypothesized that SGLT-2 inhibitors decrease the levels 
of potent atherogenic sd LDL-C particles by decreas-
ing TG levels and enhancing insulin sensitivity [1, 2]. If 
so, an increase in LDL-C by SGLT-2 inhibitors may be 
attributable to increases in less atherogenic lb LDL-C 
particles. Hence, we investigated the effect on plasma 
concentrations of LDL-C subspecies in type 2 diabetic 
patients treated with the SGLT-2 inhibitor, dapagliflozin, 
compared with patients treated with the dipeptidyl pepti-
dase-4 (DPP-4) inhibitor, sitagliptin.
HDL-C also has subspecies, namely HDL2-C and 
HDL3-C. Large, cholesterol-rich HDL2-C is inversely 
associated with plasma TG and insulin resistance, 
whereas small, cholesterol-poor HDL3-C is not [19]. We 
established a homogeneous assay for the direct measure-
ment of HDL3-C serum concentrations. Subtracting the 
concentration of HDL3-C from HDL-C gives the serum 
concentration of HDL2-C [20]. The second aim of the 
present study was to determine how the use of SGLT-2 




This study was a single center, open-label, randomized, 
prospective study. Dapagliflozin (5  mg) or sitagliptin 
(50 mg) was administered once daily for 12 weeks as add-
on therapy to established oral hypoglycemic drug treat-
ment (sulfonylureas, metformin, or an α-glucosidase 
inhibitor). The study was conducted in patients diag-
nosed with type 2 diabetes whose blood glucose was 
inadequately controlled despite combined treatment with 
diet/exercise and an oral hypoglycemic drug for more 
than 12  weeks prior to screening. The main inclusion 
criteria were: (1) age ≥20 years and ≤65 years, (2) diag-
nosis of type 2 diabetes at least 3 months prior to screen-
ing, and (3) HbA1c of ≥6.5% [48 mmol/mol] and ≤9.4% 
[79 mmol/mol] whilst on treatment. The main exclusion 
criteria were: (1) previous stroke or ischemic heart dis-
ease, (2) insulin use, (3) current or potential pregnancy, 
(4) an estimated glomerular filtration rate of  <60  mL/
min/1.73 m2 at the beginning of the run-in period, (5) a 
TG level of ≥600 mg/dL on the day of screening, and (6) 
users of omega-3 fatty acids. No drugs were changed dur-
ing the study period.
Measurements
Overnight fasting blood samples were obtained before 
and 12  weeks after the administration of dapagliflo-
zin or sitagliptin. LDL-C and HDL-C were measured 
by conventional direct methods. Both sd LDL-C and 
HDL3-C concentrations were measured using the homo-
geneous methods we established [15, 20]. Non HDL-C 
Keywords: Dapagliflozin, Sodium-glucose co-transporter-2 inhibitor, Small dense low-density lipoprotein-
cholesterol, High-density lipoprotein 2-cholesterol, Lipoprotein subspecies
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was estimated by subtracting the HDL-C from the total-
C concentration. Concentrations of lb LDL-C and HDL2-
C were estimated by subtracting the sd LDL-C from the 
LDL-C or subtracting the HDL3-C from the HDL-C, 
respectively [15, 20]. We have previously reported excel-
lent correlations (coefficient of correlation: r  >  0.90, 
p  <  0.0001) between measurements obtained using our 
homogeneous and the standard ultracentrifugation 
methods of measuring LDL-C and HDL-C sub-fraction 
concentrations [15, 20]. In addition, the validity of our 
homogeneous methods has been evaluated by other 
researchers [21]. Remnant-like particle-cholesterol (RLP-
C) was measured by the direct homogeneous method 
(MetaboRead, Kyowa Medex Co., Ltd., Tokyo, Japan). 
Total adiponectin was determined by immunoassay 
(Denka Seiken., Co., Ltd., Tokyo, Japan).
Statistical analysis
Data were expressed as mean ± standard deviation (SD), 
number and percentage, or percent changes after treat-
ment. Statistical analyses were performed using JMP 11.0 
(SAS Institute., Cavy, NC, USA). The unpaired t-test (for 
continuous variables) or Fisher’s exact test (for categori-
cal variables) was used for statistical analysis of differ-
ences in the baseline clinical parameters of participants 
in the dapagliflozin and sitagliptin groups. Comparison 
of plasma parameters before and after treatment was 
performed using the paired t-test, and for intergroup 
comparisons, the unpaired t-test was used for normally 
distributed data, the Mann–Whitney U test for data with 
skewed distributions. Correlations between 2 variables, 
the Pearson correlation coefficient was used for data with 
normal distribution pattern, whereas the Spearman rank-
correlation coefficient was used for data with a non-nor-
mal distribution. Differences were considered statistically 
significant at values of p < 0.05.
Results
The study included 80 participants, 62 men and 18 
women, who were randomly allocated to receive dapagli-
flozin (n = 40) or sitagliptin (n = 40). Additional file 1: 
Table  S1 lists baseline general characteristics and blood 
biochemical measurements, Additional file  1: Table  S2 
lists blood lipid levels. There were no significant dif-
ferences in general characteristics, blood biochemis-
try results, or lipid profiles between the dapagliflozin 
and sitagliptin group at baseline. Both groups exhibited 
hyperglycemia, mild obesity (BMI = 28 kg/m2), and mild 
liver dysfunction. The majority of patients had normal 
total cholesterol, LDL-C, and HDL-C levels and mild 
hypertriglyceridemia.
Table  1 lists general characteristics and blood bio-
chemical measurements and lipid levels at 12 weeks after 
treatment with dapagliflozin or sitagliptin, and how these 
changed from baseline measurements. Dapagliflozin sig-
nificantly reduced body weight (by 2.2  kg) (p  <  0.001) 
and systolic blood pressure (by 4  mmHg) (p  =  0.022), 
whereas these changes were not observed with sitag-
liptin. HbA1c levels decreased 0.75% in the dapagli-
flozin group vs. 0.63% in the sitagliptin group. Fasting 
blood glucose levels decreased by 23.5 and 18.7  mg/dL 
in the dapagliflozin and sitagliptin groups, respectively. 
These results are consistent with the results reported 
in previous clinical trials. Aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) were signifi-
cantly (p  <  0.001) decreased by dapagliflozin, while the 
liver function remained unchanged by sitagliptin treat-
ment. Hemoglobin, hematocrit and blood urea nitrogen 
were significantly increased in the dapagliflozin group 
(p  <  0.001), while this remained unchanged in the sit-
agliptin group. Dapagliflozin significantly increased 
the plasma level of adiponectin from 6.0  ±  3.4 to 
7.6 ± 4.2 ng/mL (p < 0.001), whereas sitagliptin had no 
effect on plasma adiponectin levels. Thus, there were sig-
nificantly differences between two treatment groups in 
terms of changes in ALT, AST, hemoglobin, hematocrit 
and adiponectin (p < 0.01).
Total-C, LDL-C, and apolipoprotein (apo) B were 
unchanged in both groups (Table 2). In the dapagliflozin 
group, the concentration of sd LDL-C decreased signifi-
cantly (20%, p < 0.01), whereas that of lb LDL-C increased 
significantly (18%, p < 0.05) (Fig. 1a). These changes were 
not observed in sitagliptin group. HDL-C, HDL2-C, 
apo AI, apo AII were significantly increased in dapagli-
flozin group (p < 0.05) (Fig. 2a); these changes were not 
observed in sitagliptin group (Fig. 2b). Thus, there were 
significantly differences between two treatment groups in 
terms of changes in sd LDL-C, lb LDL-C, HDL-C, HDL2-
C and apo AI (Table 2) (p < 0.05).
The correlation between the changes in LDL-C sub-
species, HDL-C subspecies and changes in clinical and 
lipid profile after 12 weeks of treatment with either dapa-
gliflozin or sitagliptin was analyzed in Tables  3 and 4, 
respectively. Dapagliflozin-mediated changes in LDL-C 
(r = 0.894, p < 0.001) and lb LDL-C (r = 0.665, p < 0.001) 
correlated with changes in apo B levels, while changes in 
sd LDL-C was negatively correlated with only changes 
in lb LDL-C (r  =  −0.690, p  <  0.001). Sitagliptin-medi-
ated changes in LDL-C (r = 0.909, p < 0.001), sd LDL-C 
(r = 0.467, p < 0.01) and lb LDL-C (r = 0.377, p < 0.05) 
were correlated with changes in apo B levels. Sitagliptin-
mediated changes in sd LDL-C were also correlated with 
changes in apo CIII level (r = 0.451, p < 0.01).
Dapagliflozin-mediated changes in HDL-C and HDL2-
C were significantly correlated with changes in apo 
AI and apo AII levels (p  <  0.05). Sitagliptin-mediated 
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changes in HDL-C was correlated with change in LDL-C 
(r =  0.555, p  <  0.001), apo B (r =  0.368, p  <  0.05), apo 
AI (r  =  0.808, p  <  0.001) and apo AII concentrations 
(r  =  0.633, p  <  0.001). Sitagliptin-mediated changes in 
HDL2-C concentrations were significantly correlated 
with changes in HbA1c (r  =  0.329, p  <  0.05) and lb 
LDL-C (r = 0.561, p < 0.001) (Tables 3 and 4).
Tables  5 and 6 lists the general characteristics and 
blood lipid levels associated with dapagliflozin use in 
patients, stratified according to ΔLDL-C (> 0 vs. ≤ 0 mg/
dL). In the increased LDL-C subgroup in which LDL-C 
concentrations increased by 14% (p  <  0.01), sd LDL-C 
decreased significantly (20%, p  <  0.05), while lb LDL-C 
concentrations increased significantly by 53% (p < 0.001) 
(Fig.  1b). In the decreased LDL-C subgroup in which 
LDL-C concentrations decreased, both sd LDL-C and 
lb LDL-C levels decreased significantly by 19 and 10%, 
respectively (p < 0.05). We compared baseline parameters 
between the increased LDL-C and the decreased LDL-C 
groups. In the increased LDL-C group, ages were signifi-
cantly younger, baseline TG and sd LDL-C levels were 
significantly higher, and baseline apo AI, HDL2-C and lb 
LDL-C levels were significantly lower than the decreased 
LDL-C group (p < 0.05) (Tables 5 and 6).
Discussion
Changes in LDL‑C and its subspecies after SGLT‑2 inhibitor 
treatment
Several phase III studies of SGLT-2 inhibitors—with 
larger sample sizes—have demonstrated that SGLT-2 
inhibitors elevate LDL-C levels [5, 6]. Increased LDL-C 
might increase atherogenic risk in patients treated with 
SGLT-2 inhibitors. Conversely, the majority of stud-
ies have demonstrated that SGLT-2 inhibitors reduce 
TG and increase HDL-C levels, which reduce athero-
genic risk [2, 22]. TG-lowering agents, such as fibrates 
and omega-3 fatty acids, have a tendency to increase 
LDL-C [23, 24] probably because of reduced lipid trans-
fer between TG-rich lipoprotein (TRL)-TG and LDL-C 
[25]. Therefore, it is not surprising that reduced levels 
of TG associated with SGLT-2 inhibitor use resulted in 
suppressed generation of cholesterol-poor LDL parti-
cles. Another possible mechanism for increases in LDL-C 
concentrations induced by SGLT-2 inhibitors is an ame-
lioration of insulin resistance by reducing body weight 
and glucose toxicity [1, 2]. Enhanced insulin sensitivity 
increases lipoprotein lipase activity, stimulating conver-
sion from very-low-density lipoprotein-C to LDL-C [26]. 
It is of interest that an insulin sensitizer, pioglitazone, 
Table 1 Clinical parameters before and after administration of dapagliflozin or sitagliptin
Data are expressed as mean ± standard deviation or percent changes after the treatment
BW body weight, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, Hb hemoglobin, Ht hematocrit, AST aspartate aminotransferase, ALT alanine 
aminotransferase, γGTP γ-glutamyltranspeptidase, BUN blood urea nitrogen, Cre creatinine, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose
a p values for the intragroup comparison (pre vs. post treatment values in dapagliflozin or sitagliptin group, * p < 0.05)
b p values for intergroup comparison (dapagliflozin vs. sitagliptin group in the changes from pre to post treatment, * p < 0.05)
Dapagliflozin (n = 40) Sitagliptin (n = 40) p valueb
Pre treatment Post treatment % change p valuea Pre treatment Post treatment % change p valuea
BW (kg) 78.4 ± 14.3 76.2 ± 1.8 −2.8 <0.001* 77.6 ± 11.6 77.7 ± 11.6 0.1 0.089 0.042*
SBP (mmHg) 130.7 ± 15.8 126.5 ± 12.7 −3.2 0.022* 133.2 ± 17.8 131.0 ± 13.3 −1.7 0.611 0.031*
DBP (mmHg) 86.9 ± 10.7 82.3 ± 16.0 −5.3 0.188 88.1 ± 9.5 84.4 ± 11.0 −4.2 0.024* 0.242
HR (bpm) 82.5 ± 10.4 81.6 ± 13.9 −1.1 0.300 81.5 ± 10.3 77.1 ± 10.8 −5.4 0.056 0.344
Hb (mg/dL) 14.4 ± 1.2 15.1 ± 1.4 4.9 <0.001* 14.2. ± 1.4 14.5 ± 1.5 2.1 0.088 <0.001*
Ht (%) 41.9 ± 3.5 44.5 ± 4.0 6.2 <0.001* 41.4 ± 4.3 41.9 ± 4.2 1.2 0.297 <0.001*
AST (IU/L) 34.5 ± 19.4 26.8 ± 12.8 −22.3 <0.001* 33.2 ± 9.8 35.4 ± 14.9 6.6 0.089 <0.001*
ALT (IU/L) 46.6 ± 37.0 33.5 ± 24.9 −28.1 <0.001* 42.8 ± 15.0 44.9 ± 18.4 4.9 0.202 <0.001*
γGTP (IU/L) 53.2 ± 43.0 42.3 ± 47.2 −20.5 0.109 50.9 ± 18.1 52.2 ± 22.0 2.6 0.729 0.107
BUN (mg/dL) 14.6 ± 4.3 16.8 ± 5.0 15.1 <0.001* 13.5 ± 4.5 15.3 ± 4.6 13.3 0.115 0.367
Cre (mg/dL) 0.72 ± 0.17 0.74 ± 0.23 2.8 0.173 0.77 ± 0.17 0.81 ± 0.18 5.2 0.110 0.757
eGFR (mL/
min/1.73 m2)
86.2 ± 18.4 83.6 ± 23.2 −3.0 0.230 83.5 ± 22.7 79.2 ± 21.4 −5.1 0.003* 0.545
FPG (mg/dL) 145.8 ± 47.8 122.3 ± 24.9 −16.1 0.002* 144.9 ± 57.9 126.2 ± 43.9 −12.9 0.043* 0.673
HbA1c (%) 7.61 ± 1.15 6.86 ± 0.81 −9.9 <0.001* 7.55 ± 1.64 6.92 ± 1.20 −8.3 0.006* 0.378
C-peptide (ng/mL) 2.79 ± 1.39 2.40 ± 1.56 −14.0 0.018* 2.70 ± 1.25 2.78 ± 1.48 3.0 0.633 0.190
Adiponectin (ng/mL) 6.0 ± 3.4 7.6 ± 4.2 26.7 <0.001* 6.2 ± 5.3 6.2 ± 3.8 0 0.899 0.002*
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increases LDL-C levels by stimulating LDL-C produc-
tion—most likely because of enhanced lipoprotein lipase 
activity [27, 28]. Very recently, Briand et al. [29] reported 
that empagliflozin reduced LDL receptor-mediated LDL 
clearance by the liver in hamsters fed atherogenic diets. 
Taken together, the possible mechanisms for increased 
LDL-C levels are: (1) increased LDL-C production by 
enhanced lipoprotein lipase activity, (2) suppressed con-
version from cholesterol-rich lb LDL-C to cholesterol-
poor sd LDL-C, and (3) impaired LDL-C catabolism by 
reduced LDL receptors.
We did not observe associated increases in LDL-C lev-
els with the use of dapagliflozin treatment in this study. 
The individuals whose LDL-C levels were elevated after 
dapagliflozin treatment had higher TG levels than those 
whose LDL-C levels were declined, suggesting criti-
cal role of TG in SGLT2 inhibitor-induced elevation 
of LDL-C. In addition, there were significantly differ-
ences in sd LDL-C, HDL-C, HDL2-C and lb LDL-C lev-
els between the increased LDL-C and decreased LDL-C 
subgroups. Higher TG, higher sd LDL-C and lower large 
sized HDL-C levels are usually observed in the patients 
who have more visceral obesity [30]. It is known that East 
Asian type 2 diabetes is characterized by generally lesser 
obesity and higher insulin sensitivity compared with 
Caucasians [31]. Therefore, our study is not unusual, and 
a report from Asian country has also shown that SGLT2 
inhibitor unchanged LDL-C concentrations [32].
Despite unchanged levels of LDL-C, dapagliflozin 
markedly decreased the levels of potent atherogenic sd 
LDL-C and increased levels of the less atherogenic lb 
LDL-C. Lb LDL-C levels were further elevated in the 
subset of patients whose LDL-C levels were increased 
during dapagliflozin treatment. This would be due to 
decreased LDL-C catabolism in these patients [29]. Our 
results imply that lb LDL-C is the sole contributor to ris-
ing LDL-C levels in patients using SGLT-2 inhibitors. 
Even though lb LDL-C is less atherogenic than sd LDL-
C, an increase in lb LDL-C could increase cardiovascular 
risk. However, the Quebec Cardiovascular study revealed 
that increased lb LDL-C was not positive risk factor but, 
in fact, a negative risk factor for cardiovascular death 
[33]. We failed to demonstrate a significant association 
between changes in TG and changes in LDL-C subspe-
cies during dapagliflozin treatment. However, TG levels 
fluctuate over the course of a day and postprandial TG 
levels also influence LDL-C size [34]. Thus, it is possi-
ble that dapagliflozin suppresses postprandial TG lev-
els, which affect LDL-C subspecies more strongly than 
fasting TG levels do. Consistent with previous reports 
Table 2 Lipid parameters before and after administration of dapagliflozin or sitagliptin
Data are expressed as mean ± standard deviation or percent changes after the treatment
Total-C total-cholesterol, TG triglycerides, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, Apo apolipoprotein, RLP-C remant-
like particles-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-
density lipoprotein 3-cholesterol
a p values for the intragroup comparison (pre vs. post treatment values in dapagliflozin or sitagliptin group, * p < 0.05)
b p values for intergroup comparison (dapagliflozin vs. sitagliptin group in the changes from pre to post treatment, * p < 0.05)
Dapagliflozin (n = 40) Sitagliptin (n = 40) p valueb
Pre treatment Post treatment % change p valuea Pre treatment Post treatment % change p valuea
Total-C (mg/dL) 193.5 ± 36.6 198.4 ± 45.9 2.5 0.863 192.5 ± 58.2 195.5 ± 38.9 1.6 0.720 0.102
TG (mg/dL) 152.6 ± 63.7 133.7 ± 75.8 −12.4 0.145 150.2 ± 85.2 144.6 ± 87.2 −3.7 0.245 0.928
HDL-C (mg/dL) 48.4 ± 11.1 53.5 ± 13.0 10.5 <0.001* 50.3 ± 9.25 50.3 ± 11.1 0 0.948 0.003*
LDL-C (mg/dL) 118.2 ± 32.1 118.8 ± 39.7 0.5 0.875 120.2 ± 35.1 114.7 ± 33.1 −4.6 0.257 0.323
Non HDL-C (mg/dL) 145.1 ± 36.0 144.9 ± 439 −0.1 0.947 142.2 ± 57.3 145.1 ± 38.4 2.9 0.717 0.328
Apo AI (mg/dL) 133.5 ± 21.6 143.5 ± 22.6 7.5 0.002* 134.9 ± 25.2 128.8 ± 30.7 −4.5 0.135 0.002*
Apo AII (mg/dL) 29.7 ± 4.5 30.9 ± 5.0 4.0 0.022* 30.5 ± 7.2 30.5 ± 7.2 0 0.945 0.148
Apo B (mg/dL) 100.1 ± 24.5 100.8 ± 28.1 0.7 0.777 102.3 ± 27.7 97.4 ± 26.5 −4.8 0.123 0.131
Apo CII (mg/dL) 4.8 ± 1.7 4.9 ± 2.2 2.1 0.362 5.4 ± 2.8 5.1 ± 2.6 −5.6 0.197 0.105
Apo CIII (mg/dL) 10.5 ± 3.2 11.4 ± 4.3 8.6 0.021* 10.1 ± 4.5 9.6 ± 4.0 −5.0 0.335 0.028*
Apo E (mg/dL) 4.4 ± 1.2 4.4 ± 1.5 0 0.530 4.3 ± 1.5 4.1 ± 1.0 −4.7 0.296 0.216
RLP-C (mg/dL) 6.8 ± 4.3 6.4 ± 5.1 −5.9 0.620 6.9 ± 8.0 6.1 ± 5.7 −11.6 0.303 0.750
HDL2-C (mg/dL) 26.1 ± 8.2 30.8 ± 10.8 18.0 <0.001* 26.6 ± 7.9 27.5 ± 8.4 3.4 0.334 0.013*
HDL3-C (mg/dL) 22.2 ± 3.9 22.7 ± 5.0 2.3 0.527 23.3 ± 5.2 22.2 ± 5.3 −4.7 0.132 0.130
sd LDL-C (mg/dL) 54.4 ± 24.6 43.6 ± 24.4 −19.9 0.005* 54.0 ± 22.5 50.4 ± 22.4 −6.7 0.368 0.003*
lb LDL-C (mg/dL) 63.8 ± 27.6 75.1 ± 34.1 17.7 0.026* 66.2 ± 26.3 64.3 ± 24.1 −2.9 0.671 0.029*
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[35, 36], dapagliflozin decreased body weight and liver 
transaminase levels, and increased adiponectin concen-
trations. Non-alcoholic fatty liver disease (NAFLD) is 
the most common cause of elevated liver transaminase 
levels. NAFLD covers a spectrum, ranging from simple 
stenosis in the absence of inflammation to non-alcoholic 
steatohepatitis (NASH). Many large population-based 
studies have convincingly demonstrated that an ele-
vated serum level of liver transaminase, especially ALT, 
is a common laboratory surrogate marker for NAFLD 
and NASH [37]. Patients who have NAFLD or NASH 
with increased concentrations of sd LDL-C [38, 39] and 
decreased concentrations of adiponectin [40], carry an 
additional cardiovascular risk. In this study, average liver 
transaminase levels were significantly decreased after 
the administration of dapagliflozin. In addition, AST was 
reduced in 65%, and ALT was reduced in 73% of patients. 
This suggests that the protective effects of dapagliflozin 
on atherogenic fatty liver disease including NAFLD or 
NASH, occurred concomitantly with type 2 diabetes. 
We failed to observe a significant correlation between 
changes in clinical parameters and changes in the LDL-C 
subspecies. A decrease in sd LDL-C mediated by SGLT-2 
inhibitors would be involved in multiple ameliorations of 
insulin resistance, hypertriglyceridemia, and liver steato-
sis, which synergistically contribute to suppressed gen-
eration of this potent atherogenic lipoprotein.
Changes in HDL‑C and its subspecies after SGLT‑2 inhibitor 
treatment
It is well documented that SGLT-2 inhibitors increase 





































































a Dapagliflozin group (n=40)
b Dapagliflozin subgroup (increased LDL-C group) (n=20)
Pre treatment Post treatment Pre treatment Post treatment Pre treatment Post treatment
Pre treatment Post treatment Pre treatment Post treatment  Pre treatment Post treatment
Fig. 1 Effects of dapagliflozin on LDL-C and its subspecies. Data are expressed as mean ± standard deviation. LDL-C and its subspecies values in 
the dapagliflozin group (a) or subgroup whose LDL-C was increased by dapagliflozin treatment (b) were compared between before and after the 
treatment. *p < 0.05, **p < 0.01, ***p < 0.001 (pre vs. post treatment values). LDL-C low-density lipoprotein-cholesterol, sd LDL-C small dense LDL-
cholesterol, lb LDL-C large buoyant LDL-cholesterol
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changes in HDL-C subspecies. The present study has, 
for the first time, revealed that dapagliflozin specifically 
increased HDL2-C without affecting HDL3-C. It remains 
to be proven which HDL2-C or HDL3-C particles are 
more atheroprotective. Nevertheless, it is known that, 
while HDL2-C levels are sensitive to and decreased by 
increases in plasma TG levels [19], adiposity [41], insu-
lin resistance, and are associated with a low risk for inci-
dent of type 2 diabetes [42], HDL3-C levels remain fairly 
constant. Therefore, HDL2-C inversely reflects meta-
bolic burden leading to the development of atherosclero-
sis. Selective increases in HDL2-C by dapagliflozin may 
imply ameliorations of hypertriglyceridemia, overweight 
and insulin resistance, which are also implicated as pos-
sible mechanisms for reduced sd LDL-C concentrations.
Recently, a meta-analysis of 21 phase 2b/3 dapagliflo-
zin clinical trials indicated no increased risk for major 
adverse cardiovascular events with dapagliflozin [43]. 
Recent report also indicate that dapagliflozin treatment 
for up to 104 weeks was well tolerated in older patients 
[44], who are included in a high-risk population for car-
diovascular diseases. Additionally, dapagliflozin treat-
ment was associated with reduction of oxidative stress in 
patients with type 2 diabetes, which may benefit the car-
diovascular system [45]. The favourable or neutral effects 
of dapagliflozin on the cardiovascular diseases risk found 
in this study may be associated with blood lipid profiles 
after dapagliflozin treatment.
Changes in lipid profiles after sitagliptin treatment
We evaluated the effect of a DPP-4 inhibitor, sitagliptin, 
on plasma lipids and subspecies of LDL-C and HDL-
C. Nakamura et  al. [46] reported that 25, 50, 100  mg/
day of sitagliptin treatment did not change the TG and 
LDL-C levels. Conversely, the treatment significantly 
reduced HDL-C levels for 12 months. Our present study 
showed that sitagliptin exhibited neutral effect on lipids 
and the subspecies of lipoproteins, which is in keeping 
with previous reports [47, 48]. Interestingly, Matikainen 
et  al. reported that vildagliptin suppressed postprandial 
increases in TG [49], and that this suppression was asso-
ciated with an increase in LDL-C particle diameter [50]. 
The conflicting result may be in part due to the amount 
of sitagliptin administrated. We used 50  mg/day of sit-
agliptin as a standard dose for Japanese patients, while 
100  mg/day is the standard dose of sitagliptin in West-
ern countries. Nevertheless, the results obtained from 
the sitagliptin-treated group may strengthen the validity 
of the results that dapagliflozin powerfully alters LDL-C 
and HDL-C subspecies.
Table 3 Correlation between the changes of LDL-C subspecies, HDL-C subspecies and the changes of clinical parameters
r coefficient of correlation, BW body weight, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyltranspeptidase, LDL-C low-density 
lipoprotein-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol, HDL-C high-density lipoprotein-cholesterol, HDL2-C high-
density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol
* p < 0.05
Dapagliflozin Sitagliptin
ΔLDL‑C (mg/dL) Δsd LDL‑C (mg/
dL)
Δlb LDL‑C (mg/dL) ΔLDL‑C (mg/dL) Δsd LDL‑C (mg/dL) Δlb LDL‑C (mg/
dL)
r p r p r p r p r p r p
ΔBW (kg) 0.042 0.795 −0.191 0.241 0.174 0.287 0.088 0.588 −0.084 0.607 0.017 0.917
ΔHbA1c (%) 0.109 0.506 −0.118 0.472 0.168 0.305 0.217 0.190 −0.025 0.088 0.280 0.087
ΔC-peptide (ng/mL) 0.208 0.229 0.130 0.455 0.055 0.750 0.516 0.023* −0.133 0.586 0.648 0.002*
ΔAST (IU/L) 0.008 0.957 −0.019 0.906 −0.019 0.906 0.188 0.388 0.286 0.195 −0.138 0.527
ΔALT (IU/L) 0.038 0.816 0.167 0.308 −0.097 0.555 0.026 0.906 0.232 0.297 −0.210 0.334
ΔγGTP (IU/L) 0.220 0.176 0.186 0.256 0.020 0.900 0.291 0.177 0.465 0.029* −0.267 0.217
ΔHDL‑C (mg/dL) ΔHDL2‑C (mg/dL) ΔHDL3‑C (mg/
dL)
ΔHDL‑C (mg/dL) ΔHDL2‑C (mg/dL) ΔHDL3‑C (mg/
dL)
r p r p r p r p r p r p
ΔBW (kg) −0.189 0.247 −0.208 0.203 0.002 0.986 0.107 0.509 −0.098 0.545 −0.221 0.169
ΔHbA1c (%) −0.046 0.780 −0.073 0.656 0.036 0.826 0.263 0.109 0.329 0.043* 0.148 0.378
ΔC-peptide (ng/mL) −0.074 0.671 −0.165 0.342 0.127 0.463 0.095 0.698 0.255 0.291 −0.300 0.211
ΔAST (IU/L) 0.220 0.178 0.220 0.177 0.029 0.860 −0.394 0.062 −0.347 0.104 0.072 0.742
ΔALT (IU/L) 0.164 0.316 0.168 0.306 0.017 0.915 −0.289 0.180 −0.263 0.225 0.052 0.810
ΔγGTP (IU/L) 0.197 0.227 0.153 0.350 0.095 0.563 0.201 0.570 −0.180 0.395 0.222 0.308
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Study limitations
Limitations of this study included the small number of 
study patients and short treatment period. Therefore, 
further studies are needed to verify the findings in this 
study.
Conclusions
In conclusion, an SGLT-2 inhibitor, dapagliflozin sup-
pressed potent atherogenic sd LDL-C and increased 
HDL2-C. Although LDL-C was elevated by treatment 
with dapagliflozin, this increase was solely attributable 
Table 4 Correlation between the changes of LDL-C subspecies, HDL-C subspecies and the changes of lipid parameters
r coefficient of correlation, TG triglycerides, LDL-C low-density lipoprotein-cholesterol, sd LDL-C small dense LDL-cholesterol, lb LDL-C large buoyant LDL-cholesterol, 
Apo apolipoprotein, HDL-C high-density lipoprotein-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 3-cholesterol
* p < 0.05
Dapagliflozin Sitagliptin




r p r p r p r p r p r p
ΔTG (mg/dL) 0.085 0.604 0.008 0.959 0.055 0.736 0.125 0.430 0.155 0.345 −0.009 0.953
ΔLDL-C (mg/dL) 0.080 0.625 0.665 <0.001* 0.425 0.006* 0.507 0.001*
Δsd LDL-C (mg/dL) 0.080 0.625 −0.690 <0.001* 0.425 0.006* −0.324 0.043*
Δlb LDL-C (mg/dL) 0.665 <0.001* −0.690 <0.001* 0.507 0.001* −0.324 0.043*
Δapo AI (mg/dL) 0.320 0.046* 0.280 0.084 0.022 0.890 0.301 0.073 0.044 0.795 0.013 0.938
Δapo AII (mg/dL) 0.466 0.002* 0.270 0.095 0.135 0.410 0.584 <0.001* 0.241 0.150 0.198 0.238
Δapo B (mg/dL) 0.894 <0.001* 0.078 0.639 0.592 <0.001* 0.909 <0.001* 0.467 0.003* 0.377 0.021*
Δapo CIII (mg/dL) 0.316 0.049 0.247 0.128 0.044 0.787 0.287 0.084 0.451 0.005* −0.135 0.422
ΔHDL‑C (mg/dL) ΔHDL2‑C (mg/dL) ΔHDL3‑C (mg/dL) ΔHDL‑C (mg/dL) ΔHDL2‑C (mg/dL) ΔHDL3‑C (mg/
dL)
r p r p r p r p r p r p
ΔTG (mg/dL) −0.156 0.341 −0.125 0.446 −0.069 0.674 −0.176 0.277 −0.074 0.646 −0.228 0.155
ΔLDL-C (mg/dL) 0.295 0.067 0.167 0.306 0.239 0.142 0.555 <0.001* 0.254 0.113 0.307 0.053
Δsd LDL-C (mg/dL) 0.183 0.262 −0.066 0.688 0.411 0.009* 0.192 0.240 −0.036 0.825 0.392 0.013*
Δlb LDL-C (mg/dL) 0.760 0.641 0.171 0.297 −0.134 0.413 0.288 0.071 0.561 <0.001* 0.307 0.053
Δapo AI (mg/dL) 0.890 <0.001* 0.697 <0.001* 0.450 0.004* 0.808 <0.001* 0.516 0.002* 0.489 0.003*
Δapo AII (mg/dL) 0.647 <0.001* 0.394 0.012* 0.500 0.001* 0.633 <0.001* 0.354 0.034* 0.446 0.007*
ΔapoB (mg/dL) 0.283 0.080 0.240 0.141 0.105 0.522 0.368 0.019* 0.135 0.406 0.230 0.153
ΔapoCIII (mg/dL) 0.309 0.055 0.234 0.149 0.156 0.340 0.132 0.415 0.026 0.871 0.100 0.538
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to elevations in levels of the less atherogenic lb LDL-C. 
However, these findings were not observed after treat-
ment with DPP-4 inhibitor, sitagliptin. Therefore, the use 
of new type of glucose-lowering agent, SGLT-2 inhibitor 
is unlikely to increase atherogenic risk.
Abbreviations
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Fig. 2 Effects of dapagliflozin and sitagliptin on HDL-C and its subspecies. Data are expressed as mean ± standard deviation. HDL-C and its subspe-
cies values in the dapagliflozin group (a) or sitagliptin group (b) were compared between before and after the treatment. ***p < 0.001 (pre vs. post 
treatment values). HDL-C high-density lipoprotein-cholesterol, HDL2-C high-density lipoprotein 2-cholesterol, HDL3-C high-density lipoprotein 
3-cholesterol
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